- Home
- KZIA vs CANF Comparison
KZIA vs CANF Comparison
Compare KZIA & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- CANF
- Stock Information
- Founded
- KZIA 1994
- CANF 1994
- Country
- KZIA Australia
- CANF Israel
- Employees
- KZIA N/A
- CANF N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- CANF Health Care
- Exchange
- KZIA Nasdaq
- CANF Nasdaq
- Market Cap
- KZIA 9.0M
- CANF 9.6M
- IPO Year
- KZIA 1999
- CANF N/A
- Fundamental
- Price
- KZIA $7.20
- CANF $0.59
- Analyst Decision
- KZIA Strong Buy
- CANF Strong Buy
- Analyst Count
- KZIA 3
- CANF 2
- Target Price
- KZIA $16.00
- CANF $14.50
- AVG Volume (30 Days)
- KZIA 299.1K
- CANF 174.9K
- Earning Date
- KZIA 11-14-2025
- CANF 11-27-2025
- Dividend Yield
- KZIA N/A
- CANF N/A
- EPS Growth
- KZIA N/A
- CANF N/A
- EPS
- KZIA N/A
- CANF N/A
- Revenue
- KZIA $1,549,158.00
- CANF $560,000.00
- Revenue This Year
- KZIA N/A
- CANF $461.72
- Revenue Next Year
- KZIA $49.25
- CANF N/A
- P/E Ratio
- KZIA N/A
- CANF N/A
- Revenue Growth
- KZIA 248983.08
- CANF N/A
- 52 Week Low
- KZIA $2.86
- CANF $0.59
- 52 Week High
- KZIA $39.05
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- KZIA 43.08
- CANF 32.24
- Support Level
- KZIA $6.20
- CANF $0.60
- Resistance Level
- KZIA $7.61
- CANF $0.64
- Average True Range (ATR)
- KZIA 0.48
- CANF 0.03
- MACD
- KZIA -0.06
- CANF 0.00
- Stochastic Oscillator
- KZIA 47.57
- CANF 2.03
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).